文献速递前列腺癌

大型多中心研究中尿液生物标志物PCA3和T2ERG在不同种族中效用差异

Racial Variation in the Utility of Urinary Biomarkers PCA3 and T2ERG in a Large Multicenter Study.
PubMed 文献 · J Urol · 2017-01-20

研究前瞻性纳入718名男性,评估在PCPT风险计算器基础上加入尿液生物标志物PCA3和T2ERG对不同种族前列腺癌预测的效用。结果显示,在非非裔美国男性中,加入PCA3或T2ERG可提高预测前列腺癌和临床有意义前列腺癌的AUC,而在非裔美国男性中未见额外获益。

要点

  • 在非非裔美国男性中,PCPT模型加入PCA3或T2ERG可提高对前列腺癌和临床有意义前列腺癌的预测效用。
  • 在非裔美国男性中,加入PCA3或T2ERG未显示额外获益。
  • 作者结论认为,新生物标志物应在不同人群队列中验证临床效用。

核心结论

  • 在非非裔美国男性中,将PCA3或T2ERG加入PCPT风险计算器可提高对前列腺癌和临床有意义前列腺癌的预测效用,但在非裔美国男性中未见额外获益。

研究设计与样本

  • 前瞻性收集718名男性的 demographics、PCPT风险评分、PCA3和T2ERG生物标志物数据及活检病理特征,作为EDRN的一部分。

主要发现

  • 在非非裔美国男性中,PCA3使前列腺癌预测AUC从0.64升至0.75(p<0.001),临床有意义前列腺癌AUC从0.69升至0.77(p<0.001)。
  • 在非非裔美国男性中,T2ERG使前列腺癌预测AUC从0.64升至0.74(p<0.001),临床有意义前列腺癌AUC从0.69升至0.73(p=0.029)。
  • 在非裔美国男性中,加入PCA3对前列腺癌预测AUC为0.75-0.77(p=0.64),对临床有意义前列腺癌AUC为0.65-0.66(p=0.74)。
  • 在非裔美国男性中,加入T2ERG对前列腺癌预测AUC为0.75-0.74(p=0.74),对临床有意义前列腺癌AUC为0.65-0.64(p=0.88)。

局限性

  • 非裔美国男性样本量小(72人)。
  • 研究为事后亚组分析,结果仅为假设生成性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To our knowledge it is unknown whether urinary biomarkers for prostate cancer have added utility to clinical risk calculators in different racial groups. We examined the utility of urinary biomarkers added to clinical risk calculators for predicting prostate cancer in African American and nonAfrican American men. MATERIALS AND METHODS: Demographics, PCPT (Prostate Cancer Prevention Trial) risk scores, data on the biomarkers data PCA3 (prostate cancer antigen 3) and T2ERG (transmembrane protease serine 2 and v-ets erythroblastosis virus E26 oncogene homolog gene fusion), and biopsy pathology features were prospectively collected on 718 men as part of EDRN (Early Detection Research Network). Utility was determined by generating ROC curves and comparing AUC values for the baseline multivariable PCPT model and for models containing biomarker scores. RESULTS: PCA3 and T2ERG added utility for the prediction of prostate cancer and clinically significant prostate cancer when combined with the PCPT Risk Calculator. This utility was seen in nonAfrican American men only for PCA3 (AUC 0.64 increased to 0.75 for prostate cancer and to 0.69-0.77 for clinically significant prostate cancer, both p <0.001) and for T2ERG (AUC 0.64-0.74 for prostate cancer, p <0.001, and 0.69-0.73 for clinically significant prostate cancer, p = 0.029). African American men did not have an added benefit with the addition of biomarkers, including PCA3 (AUC 0.75-0.77, p = 0.64, and 0.65-0.66, p = 0.74) and T2ERG (AUC 0.75-0.74, p = 0.74, and 0.65-0.64, p = 0.88), for prostate cancer and clinically significant prostate cancer, respectively. Limitations include the small number of African American men (72). The post hoc subgroup analysis nature of the study limited findings to being hypothesis generating. CONCLUSIONS: As novel biomarkers are discovered, clinical utility should be established across demographically diverse cohorts.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. O'Malley PG, Nguyen DP, Al Hussein Al Awamlh B, et al. Racial Variation in the Utility of Urinary Biomarkers PCA3 and T2ERG in a Large Multicenter Study. J Urol. 2017. PMID: 28115190. doi:10.1016/j.juro.2017.01.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。